Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire) - May 15, 2024 - "UPCOMING EXPECTED EVENTS AND MILESTONES:...(i) Complete ReSPECT-LM Phase 1 dose escalation trial enrollment, determine the maximum tolerated and recommended Phase 2 dose, and determine the multiple dosing regime; (ii) Report results of preclinical combination studies of rhenium (186Re) obisbemeda with PD-1 and PD-L1 checkpoint inhibitors; (iii) Secure contract with second GMP manufacturing supplier to ensure ample rhenium (186Re) obisbemeda supply for pivotal trials and commercial readiness."
Licensing / partnership • Preclinical • Trial status • Brain Cancer • CNS Tumor
|